Oppenheimer Starts Y-mAbs Therapeutics (YMAB) at Outperform
Tweet Send to a Friend
Oppenheimer analyst Jeff Jones initiates coverage on Y-mAbs Therapeutics (NASDAQ: YMAB) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
